- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04640545
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial is a multi-center, single-arm, open-label, dose-escalation and expansion phase I study of LBL-007 combined with Toripalimab and Axitinib in the treatment of unresectable or metastatic melanoma.
It is divided into Study Part A and Study Part B. The safety, tolerability, kinetic characteristics, immunogenicity and preliminary efficacy of the subjects were evaluated. Both study part A and study part B are studied in two phases: dose escalation and dose expansion
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ting Lv
- Phone Number: 025-83378099-829
- Email: lvting@leadsbiolabs.com
Study Contact Backup
- Name: Xiangyu Ma
- Phone Number: 025-83378099-828
- Email: maxy@leadsbiolabs.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Xiangyu Ma
- Phone Number: 025-83378099-828
- Email: maxy@leadsbiolabs.com
-
Contact:
- Ting Lv
- Phone Number: 025-83378099-829
-
-
Fujian
-
Fuzhou, Fujian, China, 350000
- Recruiting
- Fujian Cancer Hospital
-
Contact:
- ting lv
- Phone Number: 025-83378099
- Email: lvting@leadsbiolabs.com
-
Contact:
- xiangyu ma
- Phone Number: 025-83378099
- Email: maxy@leadsbiolabs.com
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Contact:
- xiangyu ma
- Phone Number: 02583378099
- Email: maxy@leadsbiolabs.com
-
Contact:
- ting lv
- Phone Number: 02583378099
- Email: lvting@leadsbiolabs.com
-
-
Hunan
-
Changsha, Hunan, China, 410006
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Xiangyu Ma
- Phone Number: 025-83378099-828
- Email: maxy@leadsbiolabs.com
-
Contact:
- Ting Lv
- Phone Number: 025-83378099-829
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Nanjing Drum Tower Hospital
-
Contact:
- ting lv
- Phone Number: 025-83378099
- Email: lvting@leadsbiolabs.com
-
Contact:
- xiangyu ma
- Phone Number: 025-83378099
- Email: maxy@leadsbiolabs.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- xiangyu ma
- Phone Number: 02583378099
- Email: maxy@leadsbiolabs.com
-
Contact:
- ting lv
- Phone Number: 02583378099
- Email: lvting@leadsbiolabs.com
-
Changchun, Jilin, China, 130021
- Recruiting
- Jilin Cancer Hospital
-
Contact:
- ting lv
- Phone Number: +862583378099
- Email: lvting@leadsbiolabs.com
-
Contact:
- xiangyu ma
- Phone Number: 02583378099
- Email: maxy@leadsbiolabs.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Xiangyu Ma
- Phone Number: 025-83378099-828
- Email: maxy@leadsbiolabs.com
-
Contact:
- Ting Lv
- Phone Number: 025-83378099-829
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willingness to provide written informed consent and follow the study treatment plan and visit plan;
- Aged ≥ 18 years at time of signing informed consent, male or female;
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1;
- Have life expectancy of at least 12 weeks ;
- Subject with at least one measurable tumor lesion,according to the evaluation standard of solid tumor efficacy (RECIST 1.1).
Exclusion criteria:
- Subjects are allergic to LBL-007, PD-1 and similar compounds or any component in the prescription;
- Subjects with active central nervous system metastases (regardless of whether they have received treatment), including symptomatic brain metastases, meningeal metastases, or spinal cord compression, but asymptomatic brain metastases (no progression and/or at least 4 weeks after radiotherapy) No neurological symptoms or signs after surgical resection, and dexamethasone or mannitol treatment is not required);
- Have received major surgery within 4 weeks before the first administration;
- Subjects can not tolerate intravenous administration and have difficulty in venous blood collection (if there is a history of fainting needles and bleeding);
- Women during pregnancy or lactation;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LBL-007+Toripalimab+Axitinib Tablets
Study Part A: LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv; Study Part B: LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv+Axitinib Tablets 5mg + Axitinib Tablets 1mg |
LBL-007 will be administered intravenously every two weeks (Q2W) at doses of Dose A, Dose B, Dose C,Dose D .
Toripalimab Injection will be administered by intravenously (Q2W) by the fixed dose of 3 mg/kg .
Axitinib Tablets 5mg and Axitinib Tablets 1mg(On-demand administration)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: During the first two Cycles(each cycle is 14 days)
|
MTD is defined as the hightest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first two cycles.
|
During the first two Cycles(each cycle is 14 days)
|
Number of subjcects with adverse events and serious adverse events
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
The safety profile of LBL-007 and Toripalimab will be assessed by monitoring the adverse event(AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE)v5.0
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Dose-limiting toxicities (DLT)
Time Frame: During the first two Cycles(each cycle is 14 days)
|
DLT is defined as a toxicities(adverse event at least possibly related to LBL-007 and Toripalimab )occurring during the DLT observation period(the initial 28 days).
|
During the first two Cycles(each cycle is 14 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Defined as the percentage of subjects having a Complete Response or Partial Response(ORR, including after immunotherapy complete response (iCR) and partial response (iPR)),will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1.
and iRECIST.
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Duration of Response(DOR)
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Defined as the time from earliest date of disease response (CR 、PR、iCR、iPR) until earliest date of disease progression, as determined by investigator assessment of radiographic disease per RECIST v1.1 and iRECIST, or death from any cause, if occurring sooner than progression.
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Disease Control Rate(DCR)
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Defined as percentage of participants having CR, PR, iCR,iPR or SD as best on-study response
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Steady state Area under the serum concentration versus time curve(AUCss)
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
To determine the PK profile of LBL-007 in combination with Toripalimab
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Steady state Maximum serum concentration (Cmax,ss)
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
To determine the PK profile of LBL-007 in combination with Toripalimab
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Steady state Time to reach maximum serum concentration (Tmax,ss)
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
To determine the PK profile of LBL-007 in combination with Toripalimab
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Pharmacodynamic (PD) index
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
The PD evaluation index is the LAG-3 receptor occupancy rate in peripheral blood
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Immunogenicity index
Time Frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
The immunogenicity evaluation indicators are the incidence of anti-drug antibodies (ADA) and the incidence of neutralizing antibodies (if applicable) in the subject.
|
All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jun Guo, Prof, Peking University Cancer Hospital & Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LBL-007-CN-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Melanoma
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)United States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Regeneron PharmaceuticalsBristol-Myers SquibbCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Metastatic Melanoma | Advanced Non-hematologic MalignanciesUnited States
-
University of Colorado, DenverMerck Sharp & Dohme LLCActive, not recruitingStage IV Melanoma | Advanced Melanoma | Stage III MelanomaUnited States
-
Azienda Ospedaliera di PerugiaNot yet recruitingAdvanced Melanoma | Early MelanomaItaly, Sweden, France, Germany, Netherlands, Poland, Spain
-
Cancer Trials IrelandCompletedMetastatic Melanoma | Advanced MelanomaIreland
-
Shanghai Junshi Bioscience Co., Ltd.UnknownMetastatic Melanoma | Advanced MelanomaChina
Clinical Trials on LBL-007
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Solid TumorChina
-
BeiGeneRecruitingEsophageal Cancer | Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma by AJCC V8 StageChina, Taiwan, Korea, Republic of, Thailand
-
BeiGeneRecruitingHead and Neck Cancer | Head and Neck Squamous Cell CarcinomaChina, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
Nanjing Leads Biolabs Co.,LtdRecruiting
-
Nanjing Leads Biolabs Co.,LtdRecruiting
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Solid TumorChina
-
Nanjing Leads Biolabs Co.,LtdRecruitingRelapsed/Refractory Multiple MyelomaChina
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Solid TumorChina